Literature DB >> 31838283

Analysis of cetuximab N-Glycosylation using multiple fractionation methods and capillary electrophoresis mass spectrometry.

Csaba Váradi1, Craig Jakes2, Jonathan Bones2.   

Abstract

Site-specific glycosylation of Cetuximab was characterized in this study using multiple fractionation methods and capillary electrophoresis coupled to mass spectrometry (CE-MS) based glycomics. IdeS digested Cetuximab with subsequent reduction was fractionated using reversed-phase chromatography resulting in 3 fragments; Fd, Lc and Fc/2. Glycan release of the different fragments was performed in 18O enriched water providing the possible quantification of site occupancy. 2-AA labelled glycan structures were annotated by CE-MS profiling in combination with exoglycosidase sequencing, revealing potential structures with terminal α-galactose and N-glycolyl-neuraminic acid (NGNA) mainly originating from the Fd fragment. Glycosylation analysis was also performed on different charge variants of Cetuximab that were separated using pH gradient cation-exchange chromatography to investigate the impact of glycosylation on the net charge of the protein.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Capillary electrophoresis; Cetuximab glycosylation; Charge variants; Peptide mapping

Year:  2019        PMID: 31838283     DOI: 10.1016/j.jpba.2019.113035

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  2 in total

1.  Post-translational modifications and glycoprofiling of palivizumab by UHPLC-RPLC/HILIC and mass spectrometry.

Authors:  Kulwinder Singh Sran; Yogita Sharma; Tejinder Kaur; Alka Rao
Journal:  J Proteins Proteom       Date:  2022-05-09

2.  [Analysis of glycan ratio of Chinese hamster ovary cell-cetuximab antigen-binding segment via rapid enzyme digestion with endo-β-N-acetylglucosaminidase F].

Authors:  Qian Cheng; Daihui Jia; Bohui Zhang; Junyan Xu; Zhe Shao; Yingfeng Huang; Xun Zou
Journal:  Se Pu       Date:  2022-02-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.